Champions Oncology (NASDAQ:CSBR) Posts Earnings Results, Beats Estimates By $0.06 EPS

Champions Oncology (NASDAQ:CSBR) issued its quarterly earnings results on Monday. The biotechnology company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.05) by $0.06, FiscalAI reports. Champions Oncology had a negative net margin of 3.94% and a negative return on equity of 57.31%. The company had revenue of $13.84 million for the quarter, compared to the consensus estimate of $12.89 million.

Here are the key takeaways from Champions Oncology’s conference call:

• Champions Oncology reported record fiscal 2026 revenue of $59.4 million, up 12%, driven by 12% growth in Study Services to $58.7 million.
• The company achieved its goal of positive adjusted EBITDA, posting $1.6 million for the year and positive adjusted EBITDA in all four quarters for the first time since fiscal 2022.
• Gross margin improved to 51% in the fourth quarter as the company reduced outsourced radiopharmaceutical costs by bringing more work in-house, a shift management expects to support further margin gains.
• Data-license revenue fell to approximately $800,000 from $4.7 million because a large prior-year transaction did not recur, although some expected revenue shifted into fiscal 2027 and the customer pipeline expanded.
• Management remains encouraged by Corellia’s therapeutic data and is pursuing venture funding or a pharmaceutical licensing partnership; however, no specific timing was provided, and the company plans to fund the subsidiary internally for fiscal 2027 if necessary.

Champions Oncology Trading Down 0.8%

NASDAQ CSBR opened at $6.08 on Tuesday. The stock has a market cap of $84.45 million, a PE ratio of -38.00 and a beta of 0.39. Champions Oncology has a 12 month low of $5.50 and a 12 month high of $8.74. The company’s 50-day moving average price is $6.06 and its 200-day moving average price is $6.18.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Champions Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Champions Oncology

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in shares of Champions Oncology during the second quarter worth approximately $103,000. Essex Investment Management Co. LLC purchased a new position in Champions Oncology during the 4th quarter worth $126,000. Jane Street Group LLC purchased a new position in Champions Oncology during the 1st quarter worth $200,000. Goldman Sachs Group Inc. bought a new stake in Champions Oncology during the 1st quarter valued at $201,000. Finally, Acadian Asset Management LLC lifted its holdings in shares of Champions Oncology by 28.7% in the 1st quarter. Acadian Asset Management LLC now owns 39,511 shares of the biotechnology company’s stock worth $341,000 after buying an additional 8,814 shares during the period. 41.30% of the stock is owned by hedge funds and other institutional investors.

About Champions Oncology

Champions Oncology, Inc engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients.